このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC

2026年11月15日 更新者:Shanghai Zhongshan Hospital

A Single-Arm, Multicenter Phase Ib Study on the Efficacy and Safety of IBI310 in Combination With Bevacizumab and Sintilimab for First-Line Treatment of Advanced Hepatocellular Carcinoma

This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.

調査の概要

詳細な説明

This is a single-arm, multicenter phase Ib study evaluating the safety and efficacy of IBI310 combined with sintilimab and bevacizumab in advanced hepatocellular carcinoma. Patients will receive IBI310 1.0 mg/kg IV on day 1 every 6 weeks plus sintilimab 200 mg IV and bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Approximately 50 patients are planned. After the first 6-10 patients are treated, the Safety Monitoring Committee (SMC) will assess safety in this subgroup and determine whether enrollment should continue.

Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, loss to follow-up, death, or other protocol-defined discontinuation, whichever occurs first, for a maximum of 24 months. Patients with initial investigator-assessed radiographic progression per RECIST v1.1 may continue study treatment if clinically stable, likely to benefit, and willing to continue; tumor response will then be assessed by iRECIST until no further benefit per investigator, intolerable toxicity, new antitumor therapy, consent withdrawal, loss to follow-up, or maximum treatment duration, whichever occurs first.

研究の種類

介入

入学 (推定)

50

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Histologically/cytologically confirmed hepatocellular carcinoma, or meeting the clinical diagnostic criteria for hepatocellular carcinoma ;
  2. Aged ≥18 years,≤75 years;
  3. ECOG performance status score of 0 or 1 point;
  4. Barcelona Clinic Liver Cancer (BCLC) stage C, or Stage B not suitable for radical surgery and/or local treatment;
  5. No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
  6. At least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria), at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
  7. Child-Pugh Class A or B(≤7);
  8. Adequate organ and bone marrow function.
  9. Expected life time is over 12 weeks.
  10. Take effective contraceptive measures
  11. Willing to attend the study and having given the ICF

Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
  2. History of hepatic encephalopathy or liver transplantation
  3. Pleural, ascites, and pericardial effusion with clinical symptoms requiring drainage
  4. HBV-DNA>2000 IU/ML or 10^4 copies/ml;Untreated positive HCV-RNA;HbsAg and anti-HCV antibody were both positive
  5. History of GI bleeding within 6 months, or severe (G3) varices at endoscopy within 3 months
  6. Arteriovenous embolism within 6 months
  7. The tumor thrombus involved both main and branch portal veins, main portal veins and mesenteric veins or inferior vena cava.
  8. Antiplatelet drugs were administered for 10 days for therapeutic purposes 2 weeks before administration
  9. Uncontrolled hypertension
  10. Unrecovered AE(>CTCAE grade 1) due to previous treatment
  11. Heart failure (NYHA Classification III-IV), or poorly controlled arrhythmias
  12. History of gastrointestinal perforation, fistula, intestinal obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  13. With lung fibrosis, interstitial lung disease, pneumoconiosis, drug-associated pneumonia and serious impairment in lung function
  14. Active tuberculosis
  15. Infected with HIV or syphilis
  16. Severe infections that are active or clinically poorly controlled
  17. Use of immunosuppressive drugs within 4 weeks prior to initial dosing
  18. Receipt of live attenuated vaccine within 4 weeks prior to randomization
  19. Significant traumatic injury or major surgical procedure within 28 days prior to randomization
  20. Other conditions that the investigator judged inappropriate for inclusion
  21. Prior immunotherapy or targeted therapy
  22. Treatment of Traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects whitin 2 weeks
  23. Pregnant or breast-feeding women

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Single-Arm

IBI310 1mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1,Q3W

IBI310 1mg/kg IV d1 Q6W

sintilimab 200 mg IV d1 Q3W

他の名前:
  • IBI308

bevacizumab 15 mg/kg IV d1,Q3W

他の名前:
  • IBI305

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Treatment Emergent Adverse Event, TEAE
時間枠:Any emergent adverse event from first dose through study completion, up to 2 years.

Safety

Any emergent adverse event from first dose through study completion, up to 2 years.
Severe Adverse Event, SAE
時間枠:Any severe adverse event from first dose through study completion, up to 2 years.

Safety

Any severe adverse event from first dose through study completion, up to 2 years.
Objective response rate (ORR)
時間枠:The proportion of patients with complete response or partial response, through study completion, up to 2 years

efficacy

The proportion of patients with complete response or partial response, through study completion, up to 2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Duration of Response(DOR)according to RECIST V1.1 criteria
時間枠:From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months

efficacy

From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
Duration of Response(DOR)according to mRECIST criteria
時間枠:From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months

efficacy

From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
Disease Control Rate(DCR) according to RECIST V1.1 criteria
時間枠:The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years

efficacy

The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
Disease Control Rate(DCR) according to mRECIST criteria
時間枠:The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years

efficacy

The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
Objective response rate (ORR) according to mRECIST criteria
時間枠:The proportion of patients with complete response or partial response, through study completion, an average of 2 years

efficacy

The proportion of patients with complete response or partial response, through study completion, an average of 2 years
Progresison Free Survival(PFS)according to RECIST V1.1 criteria
時間枠:From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months

efficacy

From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
Progresison Free Survival(PFS)according to mRECIST criteria
時間枠:From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months

efficacy

From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
Overall survival (OS)
時間枠:From the date of randomization until death from any cause, assessed up to 48 months.

efficacy

From the date of randomization until death from any cause, assessed up to 48 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Zhenggang Ren、Shanghai Zhongshan Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月6日

一次修了 (推定)

2029年1月1日

研究の完了 (推定)

2029年12月1日

試験登録日

最初に提出

2022年4月14日

QC基準を満たした最初の提出物

2022年5月5日

最初の投稿 (実際)

2022年5月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月15日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する